Speaker Profile

Ph.D., Chief Scientific Officer, Engine Biosciences

Biography
Steve joined Engine Biosciences as Chief Scientific Officer in May 2018. Prior to joining Engine, Steve was Senior Vice President and CSO at Relypsa where he developed a pipeline of gut-restricted polymer therapeutics targeting systemic diseases. Before that he was Vice President, Research Biology at Nektar Therapeutics (NASDAQ: NKTR), a leader in polymer conjugate therapeutics, where for four years he managed global oncology and pain research efforts. Prior to Nektar, he was Senior Vice President, Research at KAI Pharmaceuticals. While at KAI, Steve led discovery efforts, including the company’s lead compound for the treatment of secondary hyperparathyroidism, which served as the basis for the company’s eventual acquisition by Amgen. Earlier in his career, Steve held senior research positions at Chiron Corporation and Thios Pharmaceuticals. He holds a Ph.D. in Molecular Biology, a M.A. and B.A. in Biochemistry, all from University of Cambridge, England.

Talk
Target and Biomarker Identification Using ML and CRISPR Screening
Engine Biosciences is uniquely applying proprietary machine-learning algorithms and ultra high-throughput CRISPR-based validation technology to identify clinically relevant targets and patient selection biomarkers in oncology. In our talk we would outline the differentiating features of the technology platform and showcase case studies of successful target and biomarker discovery leading to drug development programs.


 Session Abstract – PMWC 2022 Silicon Valley


  • Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
    Session Chair: Ansuman Satpathy, Stanford University
    - Marcel Hop, Genentech
    - Noam Solomon, ImmunAI
    - Stacie Calad-Thomson, BioSymetrics
    - Andrea deSouza, Eli Lilly and Company
  • Advancing Research and Drug Discovery with UK Biobank
    Session Chair: Asha Collins, DNAnexus
    - Mahesh Pancholi, UK Biobank
  • Machine Learning for Novel Target Discovery: Unique Techniques Meet Unique Data
    Session Chair: Alex Morgan, Khosla Ventures
    - Lindsay Edwards, Relation Therapeutics
    - Kristen Fortney, BioAge
    - Quin Wills, Ochre Bio
    - Joseph Rodgers, Fountain Therapeutics
    - Calum MacRae, Atman Health
  • AI in Small Molecule Design and Screening (PANEL)
    Session Chair: Alex Zhavoronkov, Insilico Medicine
    - Jim Edwards, Janssen
    - Tommaso Mansi, Johnson & Johnson
    - Martin Emanuel Bittner, Arctoris
  • AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes (PANEL)
    Session Chair: Peter Lipsky, Ampel Bio
    - Nasim Eftekhari, City of Hope
    - Mika Newton, xCures, Inc.
    - Mark Smith, MedStar Health
    - William Oh, Sema4
  • Treating Genetics as Data: Computable, Structured Results for Precision Medicine
    - Peter DeVault, Epic
  • PMWC 2022 Showcase
    - Kevin Cho, Envisagenics, Inc.
    - Poojitha Ojamies, Novartis
    - Steve Harrison, Engine Biosciences